Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets

Page 5 of 5

01. Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Upside Potential: 242%

On May 7, Oppenheimer maintained its Outperform rating on Pliant Therapeutics, Inc. (NASDAQ:PLRX), a biopharmaceutical company, while raising the price target from $47 to $48. With the stock’s current market price at $13.44, the new price target suggests an upside potential of 242%. Pliant Therapeutics, Inc. (NASDAQ:PLRX) specializes in the discovery, development, and commercialization of innovative treatments for fibrosis and related diseases in the United States. The company’s focus on these complex medical conditions positions it as a key player in the clinical stage biopharmaceutical industry. The decision by Oppenheimer analyst Jeff Jones to raise the price target reflects confidence in Pliant Therapeutics, Inc. (NASDAQ:PLRX) ability to advance its pipeline of novel therapies for fibrosis, a challenging and often debilitating medical condition. The company’s commitment to cutting-edge research and development could potentially lead to breakthroughs in the treatment of fibrosis, offering substantial growth opportunities. Investors may find the significant upside potential attractive, especially given the company’s strategic focus and the growing need for effective therapies in the field of fibrosis. As Pliant Therapeutics, Inc. (NASDAQ:PLRX) continues to progress in its clinical trials and research, it holds promise as a noteworthy investment opportunity in the biopharmaceutical sector.

You can also look at the 10 Underperforming Stocks Insiders are Buying and the Insiders are Piling into These 10 Healthcare Stocks in 2024.

Page 5 of 5